CytomX Therapeutics, Inc. 6C1.F Stock
CytomX Therapeutics, Inc. Price Chart
CytomX Therapeutics, Inc. 6C1.F Financial and Trading Overview
CytomX Therapeutics, Inc. stock price | 1.73 EUR |
Previous Close | 1.42 EUR |
Open | 1.4 EUR |
Bid | 1.41 EUR x 200000 |
Ask | 1.44 EUR x 200000 |
Day's Range | 1.4 - 1.4 EUR |
52 Week Range | 1.12 - 2.92 EUR |
Volume | 1K EUR |
Avg. Volume | 804 EUR |
Market Cap | 92.87M EUR |
Beta (5Y Monthly) | 0.65 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0.19 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.14 EUR |
6C1.F Valuation Measures
Enterprise Value | -92959352 EUR |
Trailing P/E | N/A |
Forward P/E | -0.90909094 |
PEG Ratio (5 yr expected) | 5.06 |
Price/Sales (ttm) | 1.3734355 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | -1.375 |
Enterprise Value/EBITDA | 1.435 |
Trading Information
CytomX Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 0.65 |
52-Week Change | -2.71% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.92 EUR |
52 Week Low | 1.12 EUR |
50-Day Moving Average | 1.52 EUR |
200-Day Moving Average | 1.69 EUR |
6C1.F Share Statistics
Avg. Volume (3 month) | 804 EUR |
Avg. Daily Volume (10-Days) | 319 EUR |
Shares Outstanding | 66.34M |
Float | 53.16M |
Short Ratio | N/A |
% Held by Insiders | 1.46% |
% Held by Institutions | 57.42% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -104.47% |
Operating Margin (ttm) | -99.41% |
Gross Margin | 100.00% |
EBITDA Margin | -95.81% |
Management Effectiveness
Return on Assets (ttm) | -15.81% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 67.62M EUR |
Revenue Per Share (ttm) | 1.03 EUR |
Quarterly Revenue Growth (yoy) | 159.90% |
Gross Profit (ttm) | 53.16M EUR |
EBITDA | -64790000 EUR |
Net Income Avi to Common (ttm) | -70647000 EUR |
Diluted EPS (ttm) | -0.97 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 204.5M EUR |
Total Cash Per Share (mrq) | 3.08 EUR |
Total Debt (mrq) | 17.08M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.403 |
Book Value Per Share (mrq) | -1.306 |
Cash Flow Statement
Operating Cash Flow (ttm) | -60126000 EUR |
Levered Free Cash Flow (ttm) | 17.69M EUR |
Profile of CytomX Therapeutics, Inc.
Country | Germany |
State | CA |
City | South San Francisco |
Address | 151 Oyster Point Boulevard |
ZIP | 94080 |
Phone | 650 515 3185 |
Website | https://www.cytomx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 116 |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.
Q&A For CytomX Therapeutics, Inc. Stock
What is a current 6C1.F stock price?
CytomX Therapeutics, Inc. 6C1.F stock price today per share is 1.73 EUR.
How to purchase CytomX Therapeutics, Inc. stock?
You can buy 6C1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CytomX Therapeutics, Inc.?
The stock symbol or ticker of CytomX Therapeutics, Inc. is 6C1.F.
Which industry does the CytomX Therapeutics, Inc. company belong to?
The CytomX Therapeutics, Inc. industry is Biotechnology.
How many shares does CytomX Therapeutics, Inc. have in circulation?
The max supply of CytomX Therapeutics, Inc. shares is 78.52M.
What is CytomX Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
CytomX Therapeutics, Inc. PE Ratio is 9.10000000 now.
What was CytomX Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
CytomX Therapeutics, Inc. EPS is 0.19 EUR over the trailing 12 months.
Which sector does the CytomX Therapeutics, Inc. company belong to?
The CytomX Therapeutics, Inc. sector is Healthcare.